Cargando…

Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition

Lycorine is reported to be a multifunctional compound. We previously showed that lycorine is an HCV inhibitor with strong activity. Further research on the antivirus mechanism indicated that lycorine does not affect the enzymes that are indispensable to HCV replication but suppresses the expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Duozhi, Cai, Jieyun, Cheng, Junjun, Jing, Chenxu, Yin, Junlin, Jiang, Jiandong, Peng, Zonggen, Hao, Xiaojiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595722/
https://www.ncbi.nlm.nih.gov/pubmed/26443922
http://dx.doi.org/10.1038/srep14972
_version_ 1782393655116431360
author Chen, Duozhi
Cai, Jieyun
Cheng, Junjun
Jing, Chenxu
Yin, Junlin
Jiang, Jiandong
Peng, Zonggen
Hao, Xiaojiang
author_facet Chen, Duozhi
Cai, Jieyun
Cheng, Junjun
Jing, Chenxu
Yin, Junlin
Jiang, Jiandong
Peng, Zonggen
Hao, Xiaojiang
author_sort Chen, Duozhi
collection PubMed
description Lycorine is reported to be a multifunctional compound. We previously showed that lycorine is an HCV inhibitor with strong activity. Further research on the antivirus mechanism indicated that lycorine does not affect the enzymes that are indispensable to HCV replication but suppresses the expression of Hsc70 in the host cell to limit HCV replication. However, due to the cytotoxicity and apoptosis induction of lycorine, lycorine is unsafe to be a anti-HCV agent for clinical application. As a result of increasing interest, its structure was optimized for the first time and a novel series of lycorine derivatives was synthesized, all of which lost their cytotoxicity to different degrees. Structure-activity analysis of these compounds revealed that disubstitution on the free hydroxyl groups at C1 and C2 and/or degradation of the benzodioxole group would markedly reduce the cytotoxicity. Furthermore, an α, β-unsaturated ketone would improve the HCV inhibitory activity of lycorine. The C3-C4 double bond is crucial to the anti-HCV activity because hydrogenation of this double bond clearly weakened HCV inhibition.
format Online
Article
Text
id pubmed-4595722
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45957222015-10-13 Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition Chen, Duozhi Cai, Jieyun Cheng, Junjun Jing, Chenxu Yin, Junlin Jiang, Jiandong Peng, Zonggen Hao, Xiaojiang Sci Rep Article Lycorine is reported to be a multifunctional compound. We previously showed that lycorine is an HCV inhibitor with strong activity. Further research on the antivirus mechanism indicated that lycorine does not affect the enzymes that are indispensable to HCV replication but suppresses the expression of Hsc70 in the host cell to limit HCV replication. However, due to the cytotoxicity and apoptosis induction of lycorine, lycorine is unsafe to be a anti-HCV agent for clinical application. As a result of increasing interest, its structure was optimized for the first time and a novel series of lycorine derivatives was synthesized, all of which lost their cytotoxicity to different degrees. Structure-activity analysis of these compounds revealed that disubstitution on the free hydroxyl groups at C1 and C2 and/or degradation of the benzodioxole group would markedly reduce the cytotoxicity. Furthermore, an α, β-unsaturated ketone would improve the HCV inhibitory activity of lycorine. The C3-C4 double bond is crucial to the anti-HCV activity because hydrogenation of this double bond clearly weakened HCV inhibition. Nature Publishing Group 2015-10-07 /pmc/articles/PMC4595722/ /pubmed/26443922 http://dx.doi.org/10.1038/srep14972 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Chen, Duozhi
Cai, Jieyun
Cheng, Junjun
Jing, Chenxu
Yin, Junlin
Jiang, Jiandong
Peng, Zonggen
Hao, Xiaojiang
Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
title Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
title_full Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
title_fullStr Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
title_full_unstemmed Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
title_short Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
title_sort design, synthesis and structure-activity relationship optimization of lycorine derivatives for hcv inhibition
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595722/
https://www.ncbi.nlm.nih.gov/pubmed/26443922
http://dx.doi.org/10.1038/srep14972
work_keys_str_mv AT chenduozhi designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT caijieyun designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT chengjunjun designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT jingchenxu designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT yinjunlin designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT jiangjiandong designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT pengzonggen designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition
AT haoxiaojiang designsynthesisandstructureactivityrelationshipoptimizationoflycorinederivativesforhcvinhibition